# Synagis

NDC: 66658-231
Generic name: palivizumab
Labeler / Manufacturer: Swedish Orphan Biovitrum AB (publ)
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION, SOLUTION
Routes: INTRAMUSCULAR
Marketing started: 19980619
Marketing ended: 20260731
FDA application: BLA103770

## Active ingredients

- PALIVIZUMAB: 100 mg/mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"66658-231"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=66658-231
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=3a0096c7-8139-44cd-bba4-520ab05c2cb2